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Hormone receptor-positive breast cancer is the most frequent breast cancer subtype. 
Endocrine therapy (ET) targeting the estrogen receptor (ER) pathway represents the 
main initial therapeutic approach. The major strategies include estrogen deprivation and 
the use of selective estrogen modulators or degraders, which show efficacy in the man-
agement of metastatic and early-stage disease. However, clinical resistance associated 
with progression of disease remains a significant therapeutic challenge. Mutations of the 
ESR1 gene, which encodes the ER, have been increasingly recognized as an important 
mechanism of ET resistance, with a prevalence that ranges from 11 to 39%. The majority 
of these mutations are located within the ligand-binding domain and result in an estro-
gen-independent constitutive activation of the ER and, therefore, resistance to estrogen 
deprivation therapy such as aromatase inhibition. ESR1 mutations, most often detected 
from liquid biopsies, have been consistently associated with a worse outcome and are 
being currently evaluated as a potential biomarker to guide therapeutic decisions. At the 
same time, targeted therapy directed to ESR1-mutated clones is an appealing concept 
with preclinical and clinical work in progress.
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iNTRODUCTiON
Breast cancer is a heterogeneous disease comprising different clinical, histopathological, and 
molecular subtypes. Hormone receptor-positive (HR+) tumors represent the most common form of 
breast cancer and account for most of the deaths from the disease. Endocrine therapy (ET) is recom-
mended to virtually all patients with HR+ breast cancer. However, due to a variety of mechanisms of 
resistance, a significant proportion of patients with early-stage breast cancer experience recurrence 
despite curative-intent local therapy and long-term adjuvant ET. In the metastatic setting, although 
most patients derive benefit from initial ET, with disease stabilization or tumor shrinkage, develop-
ment of resistance invariably occurs (1). Breast tumors are known to undergo genomic evolution 
during treatment, with the acquisition of new alterations that confer resistance to therapy. ESR1, the 
gene that encodes the estrogen receptor (ER), is known to undergo ligand-binding domain (LBD) 
mutations, gene amplification, or an ESR1/YAP1 translocation that are potential mechanisms of 
resistance to ET (1, 2).
This review summarizes published and ongoing research covering ESR1 mutations in breast 
cancer, addressing epidemiological, pathophysiological issues with potential clinical implications. 
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We will explore the prospects for analysis of ESR1 mutational 
status as a prognostic and predictive biomarker as well as the 
development of therapeutic strategies targeting ESR1-mutated 
tumor cells.
THe eR PATHwAY
Estrogen receptor, a protein encoded by the ESR1 gene, is 
expressed in approximately 70% of breast cancers. ER expression 
is one of the defining features in classifying tumor subtype and 
assigning therapeutic strategies in breast cancer. A large body 
of experimental and clinical research has established the funda-
mental role of ER and its hormonal ligands in normal mammary 
gland development and in the etiology and progression of breast 
cancer (3).
Estrogen receptor is predominantly a nuclear protein that func-
tions as a ligand-dependent transcription factor. Functionally, 
the ER consists of two transcriptional activation domains: the 
N-terminal, ligand-independent activation function domain, 
and the C-terminal, ligand-dependent AF-2 domain. The LBD 
resides in the C-terminal region, while the DNA-binding and 
hinge domains are positioned in the central core of the protein 
(2). Estrogen binding triggers a number of events resulting in 
activation of ER and induces conformational changes in the 
LBD, allowing the estrogen–ER complex to bind to specific DNA 
sequences [estrogen response elements (EREs)] while interact-
ing with co-repressor and coactivator proteins to regulate the 
transcription of estrogen-responsive genes that are important 
in various physiological and pathological processes, including 
carcinogenesis and tumor progression (2, 4–6).
eT FOR ADvANCeD BReAST CANCeR: 
wHeRe ARe we?
Targeting the ER pathway with endocrine therapies may be 
considered the first molecularly targeted treatment for cancer 
and remains a mainstay of treatment for all stages of ER-positive 
disease (7). The main strategies of ET include treatments that 
result in estrogen deprivation [e.g., ovarian ablation, aromatase 
inhibitors (AIs)], drugs that antagonize the ER (e.g., tamoxifen), 
and ER downregulation (e.g., fulvestrant). Endocrine agents are 
used throughout all stages of the breast cancer clinical continuum. 
Endocrine monotherapy is standard of care as a chemoprevention 
strategy in patients with in  situ tumors, adjuvant treatment for 
patients with early-stage disease, and as treatment aiming at dis-
ease control and survival prolongation for patients with metastatic 
disease. While the benefits of ET are clearly recognized, unfortu-
nately, breast tumors are known to undergo genomic evolution, 
with the acquisition of new alterations that confer resistance to 
therapy. Therefore, a significant proportion of patients with early-
stage breast cancer experience recurrence despite local therapy 
with curative intent and long-term adjuvant ET. In the metastatic 
setting, although most patients derive benefit from initial ET, 
with disease stabilization or tumor shrinkage, subsequent lines 
of treatment result in shorter periods of response, denoting the 
development of resistance and disease progression that invariably 
occurs (1).
Recent developments in the understanding of molecular inter-
actions between ER signaling and growth factor, metabolic and 
cell-division pathways have opened the possibility of improving 
results by modulating hormone signaling and interfering with 
resistance mechanisms yet to be fully understood (7). As a result 
of some of these developments, the treatment algorithm for HR+ 
advanced breast cancer is evolving, and combinations of endo-
crine agents with targeted therapies that modulate endocrine 
resistance, such as mTOR and CDK 4/6 inhibitors, have been 
recently incorporated into clinical practice and are covered in dif-
ferent guidelines (8, 9). Major paradigms that have been guiding 
clinical practice include the sequential use of endocrine agents 
and the indication of ET in all cases, except those with impending 
visceral crisis or proven endocrine resistance. Primary endocrine 
resistance has been arbitrarily defined as a relapse while on the 
first 2 years of adjuvant ET, or PD within the first 6 months of 
first-line ET for metastatic disease. Secondary (acquired) endo-
crine resistance has been defined as a relapse while on adjuvant 
ET but after the first 2 years, or a relapse within 12 months of 
completing adjuvant ET, or as disease progression that occurs 
≥6  months after initiating ET for metastatic disease (7, 10). 
However, inter- and intra-tumor heterogeneity (11), combined 
with limitations in the design of trials conducted in this area, and 
the absence of predictive biomarkers make it difficult to develop 
a more rational approach for HR+ advanced breast cancer and to 
define the optimal sequencing of endocrine agents and whether 
endocrine therapies should be used in combination or sequence 
with targeted therapies (7, 8). Clinical recommendations about 
ET for women with HR+ advanced breast cancer have been com-
prehensively reviewed in a recent American Society of Clinical 
Oncology Clinical Practice Guideline (8).
eSR1 MUTATiONS
ESR1 mutations were first described in cell models in 1996 (12), 
when Y537S and E380Q mutations were found to confer constitu-
tive activation of the receptor and resistance to endocrine agents. 
Shortly thereafter, the Y537N mutation was found in a clinical 
sample of metastatic breast cancer (13). However, subsequent 
studies performed mainly in primary breast tumors were not able 
to identify ESR1 mutations, and the potential clinical significance 
of the abnormality remained underappreciated for more than a 
decade. Large-scale genomics efforts, such as The Cancer Genome 
Atlas (TCGA) project, have led to new insights in the landscape 
and complexity of breast cancer genomics and heterogeneity (14). 
Despite the central role of the ER in luminal tumors, TCGA data 
for 962 breast cancer samples indicated that ESR1 mutations were 
present in only 0.5% of primary breast tumor cases (15).
It was not until 2013 that a series of studies using next-
generation sequencing (NGS) of DNA renewed interest in the 
mutated receptor by demonstrating a high prevalence (11–55%) 
of ESR1 mutations in metastatic ER-positive breast cancers with 
prior AI exposure (2, 16–20). In a review by Jeselsohn et al., a 
total of 187 metastatic ER+ breast tumors from patients in five 
studies treated with at least one line of ET were described: ER 
LBD mutations were identified in 39 cases (21%) (2). In other 
published series, the prevalence of ESR1 mutations has varied 
TABLe 1 | Prevalence of eSR1m in published studies including more than 
100 patients.
Reference Number of 
patients 
(n)
eSR1m 
prevalence 
(%)
Methods
Fribbens et al. 
(PALOMA 3 cohort) (23)
360 25 Plasma circulating 
tumor DNA (ctDNA) 
ddPCR
Fribbens et al. (SOFEA 
cohort) (23)
161 39 Plasma ctDNA ddPCR
Chandarlapaty et al. 
(BOLERO-2 cohort) 
(21)
541 29 Plasma ctDNA ddPCR
Clatot (22) 144 31 Plasma ctDNA ddPCR
Spoerke (FERGI 
cohort) (25)
153 37 Plasma ctDNA ddPCR
Schiavon (24) 171 11 Plasma ctDNA ddPCR
Jeselson (2) 187 21 Metastatic tumor 
biopsies next-generation 
sequencing (NGS)
Niu (26) 222 12 Metastatic tumor 
biopsies NGS
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from 11 to 54%, mostly because of differences in patient profiles 
(see Table 1). Most recent studies analyzing ESR1 mutations in 
liquid biopsies in cohorts of clinical trials in AI-refractory HR+ 
advanced breast cancer suggest a prevalence ranging from 11 
to 39% (21–26). In contrast, ESR1 mutations have been rarely 
detected in treatment-naïve primary tumors, suggesting that 
these mutations arise either through clonal selection of very low 
abundance resistant clones or are acquired later in the disease 
course under the selective pressure of ET.
ESR1 mutations are most commonly missense mutations 
clustered in codons 537 and 538 of the LBD that result in ligand-
independent constitutive activation of the receptor. The most 
prevalent ESR1 point mutations are Y537S and D538G, while sev-
eral others have been identified at significantly lower frequencies. 
Remarkably, the majority of ESR1 mutations localize to just a few 
amino acids within or near the critical helix 12 region of the ER 
LBD, where they are likely to be single-allele mutations, as shown 
in Figure 1 (1, 27). Mutant ER recruits coactivators in the absence 
of hormone, while their affinities for estrogen agonist (estradiol) 
and antagonist (4-hydroxytamoxifen) are reduced. Further, they 
confer antiestrogen resistance by altering the conformational 
dynamics of the loop connecting Helix 11 and Helix 12 in the 
LBD of ER, which leads to a stabilized agonist state and an altered 
antagonist state that resists inhibition (28).
SUBGROUPS AT iNCReASeD RiSK OF 
DeveLOPiNG eSR1 MUTATiONS
Based on available data, it could be hypothesized that some 
factors such as previous ET exposure and patient and disease 
characteristics could be associated with an increased risk of ESR1 
mutations within patients with ER+ advanced breast cancer.
exposure to Previous endocrine Therapies
From a mechanistic point of view, two general patterns of ET 
resistance may be recognized clinically: primary (or intrinsic) 
resistance, whereby ER+ cancers never adequately respond 
to ET, and secondary (or acquired) resistance, which develops 
following an initial response (1, 29). These definitions, although 
imperfect and arbitrary, have been useful in some clinical trials 
to stratify patient populations (30). As noted above, ESR1 muta-
tions are characteristically absent in primary tumors and are an 
unlikely mechanism of primary resistance (2, 15). Most patients 
with tumors harboring ESR1 mutations seem to experience a 
protracted clinical course prior to detection of the mutation, 
supporting the idea that this is largely an acquired (secondary) 
resistance mechanism that emerges after long-term ET (31). 
Several studies have shown an association between the prevalence 
of the hot spot LBD mutations and the number of lines of ET 
(16). Interestingly, kinetic studies showed detectable circulating 
ESR1 mutations before clinical progression in 75% of the cases 
(22). If further confirmed and validated that these results may 
eventually justify earlier changes in treatment strategies based on 
liquid biopsies, before radiographic or clinical demonstration of 
disease progression.
Tamoxifen versus Ais
Based on current evidence, ESR1 mutations are chiefly a mecha-
nism of resistance to AIs rather than a non-specific mechanism 
of resistance to endocrine agents in general. ESR1 mutations have 
been identified only rarely in patients whose sole previous ET was 
tamoxifen (16, 23, 24). Although much of our understanding of 
ligand-independent ER activity comes from analysis of tamoxifen 
resistance, it must be stressed that while tamoxifen and AI resist-
ance share many common features, their effects on ER signaling 
are far from identical.
Distant versus Locoregional Disease
Early studies reported ESR1 mutations in tumor samples obtained 
from different organ sites, including lymph nodes, skin, lung, 
and liver, suggesting that these mutations do not display specific 
organotropism (2, 16–18, 20). In contrast, recently published 
multivariable analyses based on circulating DNA of patients from 
the SOFEA and PALOMA3 trials showed that the detection of 
ESR1 mutations is associated with bone and visceral disease and 
may suggest that ESR1 mutations are unfrequently detected in 
patients with nodal or loco regional recurrence only (23). These 
associations should be evaluated in further studies.
Ai exposure on the Adjuvant versus on the 
Metastatic Setting
Some studies suggest that the prevalence of ESR1 mutations 
differs markedly between patients who were first exposed to AI 
during adjuvant therapy and those exposed in the metastatic 
setting (21, 24). ESR1 mutations are rarely acquired during 
adjuvant AI (21, 24) but are commonly detected after therapy 
for metastatic disease, suggesting that mechanisms of resist-
ance to targeted therapy may be substantially different between 
the treatment of micrometastatic and overt metastatic cancer. 
FiGURe 1 | The eSR1 gene and most common mutations [reprinted with permission—Ma et al. (1)]. A schematic diagram of estrogen receptor-α (ERα) 
mutations and their frequencies in ER+ metastatic breast cancer after therapy with aromatase inhibitors and other endocrine agents. The structural domains of ERα 
are shown, including the transcription activation function 1 (AF1) domain, the DNA-binding domain (DBD), the receptor dimerization and nuclear localization (hinge) 
domain, and the ligand-binding domain (LBD), and AF2 domain.
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Schiavon et  al. explained this difference by hypothesizing that 
preexisting ESR1 mutant subclones are selected by AI therapy, but 
the tumor burden in the micrometastatic setting may be too low 
for such clones to be detected (24). This hypothesis-generating 
association should be further evaluated in prospective studies, 
even more so with the recent publication of the extension of AI 
adjuvant therapy to 10 years (32).
which subgroups are at higher risk of developing eSR1m?
– HR+ advanced breast cancer
– Resistance to AIs
– Secondary (acquired) resistance
– Long disease control interval with ET
– Aromatase inhibitors used in the metastatic setting
– Bone and visceral disease
HOw SHOULD we TeST FOR  
eSR1 MUTATiONS?
Initial studies describing ESR1 mutations were performed in 
metastatic tumor samples from retrospective cohorts and clinical 
trials. Mutations were detected by whole-genome sequencing and 
were confirmed with analysis of the originating tumors (2). With 
the potential evolution of the tumor genome through treatment, 
repeated sampling of a tumor would be required to optimally 
guide therapy, because the mechanism of resistance may not be 
evident in analyses of pre-treatment samples. Yet, serial biopsies 
of recurrent, metastatic cancer would be invasive, risky, and unac-
ceptable to many patients.
The ability to study non-hematologic cancers through 
minimally invasive sampling of blood is an exciting and rapidly 
advancing field in cancer diagnostics. These liquid biopsies have 
been driven both by major technologic advances, including the 
isolation of intact cancer cells and the analysis of cancer cell-
derived DNA from blood samples and by the increasing applica-
tion of molecularly driven therapeutics, which rely on accurate 
and timely measurements of biomarkers (33). Tumor-derived 
DNA is found in the plasma of patients with recurrent cancer, 
and in-depth analysis of circulating tumor DNA (ctDNA) 
presents a non-invasive way of analyzing tumor genetics and 
the acquisition of selected abnormalities throughout the course 
of treatment. Numerous recent reports have demonstrated 
the detection of mutant ESR1 DNA alleles as tumor-specific 
biomarkers in cell-free DNA (cfDNA) from blood (21, 23, 
24, 34–37). In this context, digital polymerase chain reaction 
(PCR)-based methods appear to be a simpler and more sensitive 
approach for ESR1 detection in ctDNA than NGS techniques 
(35, 36, 38).
eSR1 MUTATiON AS A BiOMARKeR
At the present time, there is no evidence demonstrating a role for 
specific biomarkers other than ER, PR, and HER2 in the clinical 
management of HR+ advanced breast cancer (7, 8). Use of other 
biomarkers is considered experimental and currently should be 
reserved for selection of treatment in clinical trials. Technical 
developments in sequencing ctDNA, among other ongoing 
efforts attempting to define changes induced by previous treat-
ments, will allow us to better understand what happens after HR 
signaling is altered by therapy. The availability of new sensitive 
sequencing technologies to analyze data from prospective and 
retrospective studies will provide important information on the 
clinical significance of ESR1 mutations and possibly guide the 
development of novel therapeutic strategies.
5Reinert et al. ESR1 Mutations in Breast Cancer
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PROGNOSTiC BiOMARKeR
ESR1 mutations have been consistently associated with statisti-
cally and clinically inferior outcomes in several series. Worst 
prognosis has been demonstrated as decreased progression-free 
survival (PFS) and overall survival (OS), in comparison with 
patients with wild-type ESR1.
Chandarlapaty et  al. (21) analyzed cfDNA from baseline 
plasma samples from participants in the BOLERO-2 trial. The 
two most frequent mutations in ESR1 (Y537S and D538G) were 
analyzed and samples were scored as wild-type, D538G, Y537S, 
or double-mutant. Cox proportional hazards model was used 
to assess PFS and OS in patient subgroups defined by muta-
tions. Of 541 evaluable patients, 156 (28.8%) had one or both 
ESR1 mutations (D538G in 21.1% and Y537S in 13.3%, with 
30 patients having both). These mutations were associated with 
shorter OS (wild-type, median of 32 months; D538G, median 
of 26  months; Y537S, median of 20  months; both mutations, 
median of 15 months, supporting the notion that ESR1 muta-
tions are an adverse prognostic biomarker associated with more 
aggressive disease biology). The adverse prognostic impact of 
ESR1 mutations remained after adjustment for the potential 
effects of previous hormone therapy, visceral disease, and 
performance status.
Similarly, Clatot et al. (22) reported a retrospective analysis of 
predictive and prognostic values of ESR1 circulating mutations 
(D538G and Y537S/N/C) in advanced breast cancer after pro-
gression on AI treatment. Among the 141 patients analyzed, the 
median OS was significantly shorter in patients with circulating 
ESR1 mutation (15.5 months) than in patients without mutations 
(23.8  months; P =  0.0006; hazard ratio =  1.9). The prognostic 
value of circulating ESR1 mutations at progression was confirmed 
in multivariable analysis (P = 0.002, hazard ratio = 1.9). A level of 
cfDNA above the median value and a performance status >1 were 
also identified as independent prognostic factors for OS. A worse 
PFS was observed in patients with ESR1 mutations, with a median 
of 5.9 months, compared with 7.0 months for patients without 
mutations (P = 0.002, hazard ratio = 1.7). In the multivariable 
analysis of PFS, the presence of circulating ESR1 mutation and a 
prior line of chemotherapy before AI introduction were identified 
as independent prognostic factors of worse outcome.
PReDiCTive BiOMARKeR
As mentioned before, there is no evidence to date demonstrat-
ing a role for a biomarker in selecting an optimal therapeutic 
strategy for ER-positive HER2-negative advanced breast cancer. 
Limitations associated with tumor heterogeneity and caveats in 
the design of trials conducted in this area have made it difficult 
to develop predictive biomarkers, and most of the new combina-
tions with targeted agents, even though showing improvements 
in clinical endpoints, have been directed to unselected popula-
tions of patients (39–42). However, recent data from several 
studies published over the last 2 years have brought interest in the 
potential role of ESR1 mutational status as a predictive biomarker 
and a tool to guide the clinician in therapeutic decisions. The 
ESR1 mutation behavior has also been described in small series: 
although most patients with an increase in circulating ESR1 
mutation had disease progression, not all patients with a decrease 
in ESR1 mutation responded to treatment (22, 37). Available data 
on the use of ESR1 mutation as predictive biomarkers for different 
endocrine agents are summarized in the following paragraphs.
Aromatase inhibitors
Aromatase inhibitors inhibit breast cancer growth by estrogen 
deprivation and, therefore, ESR1 mutations confer resistance to 
aromatase inhibition because they allow tumors to proliferate 
independently of estrogen. Patients with ESR1 mutations have 
a poorer PFS on subsequent AI-based therapy than patients 
without such mutations (23, 24). In a prospective–retrospective 
analysis of the SOFEA trial (43), the detection of ESR1 muta-
tions in plasma DNA predicted relative resistance to exemestane 
(23). This provides initial evidence of the potential clinical utility 
for the use of ESR1 plasma DNA analysis in selecting the most 
appropriate ET.
Tamoxifen and Fulvestrant
Preclinical studies on the effect of ER-LBD mutations have 
shown a relative resistance of the activating mutations to 
tamoxifen and fulvestrant (2, 13). On the other hand, effective 
inhibition of these mutants with higher doses of these agents 
suggests that the use of such higher doses or of more-potent 
(or mutant-specific) selective ER modulators (SERMs) or selec-
tive ER downregulators (SERDs) might benefit patients with 
tumors harboring LBD-mutated ER. In a retrospective analysis 
of patients treated with 500 mg of fulvestrant as monotherapy 
in the FERGI trial, ESR1 mutations were not associated with a 
differential PFS benefit, suggesting that they may not be strongly 
associated with clinical resistance to SERD treatment (25). In a 
prospective–retrospective analysis, Fribbens et al. (23) assessed 
ESR1mutations in available archived baseline plasma from the 
SOFEA trial, which compared exemestane with fulvestrant-
containing regimens in patients with prior sensitivity to non-
steroidal AI, and in baseline plasma from the PALOMA3 trial, 
which compared fulvestrant plus placebo versus fulvestrant plus 
palbociclib in patients with progression after receiving prior ET. 
ESR1 mutations were analyzed by multiplex digital PCR. The 
results suggest that ESR1-mutant cancers show selective sensi-
tivity to fulvestrant, a drug that degrades the ER, in comparison 
to AIs. Nonetheless, ESR1 mutants treated with fulvestrant had 
modestly worse PFS than wild-type cancers. This is consistent 
with the finding that in  vitro hot spot mutations in the LBD 
partially inhibit fulvestrant binding (18). More potent receptor 
degraders may have the potential to further improve results in 
comparison with fulvestrant in ESR1 mutant cancers, and a 
number of such therapies are in early clinical development.
Chemotherapy
The impact of ESR1 mutational status on chemotherapy has not 
been adequately studied. A French cohort evaluated 74 patients 
and also reported worse outcomes for ESR1-mutated patients 
irrespective of treatment with ET or chemotherapy. No particu-
lar benefit of chemotherapy versus tamoxifen or fulvestrant was 
seen (44).
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mTOR inhibitors
The combination of mTOR inhibitors with endocrine agents 
has been incorporated into clinical practice after the publica-
tion of the BOLERO 2 trial, a randomized phase III study 
that demonstrated significant improvement in PFS with the 
addition of the mTOR inhibitor everolimus to the steroidal AI 
exemestane (39) in patients with HR+ advanced breast cancer 
that progressed after non-steroidal AI therapy. As noted above, 
Chandarlapaty et  al. used liquid biopsies of baseline plasma 
samples of patients participating in the BOLERO2 trial (21) to 
assess the potential role of ESR1 mutations as prognostic and 
predictive biomarkers. Both Y537S and D538G mutations were 
associated with more aggressive disease biology and patients 
harboring ESR1 mutations had worst prognosis with shorter 
OS. With respect to the benefit of everolimus, the analysis 
confirmed that most patients benefit from the addition of this 
drug since both the wild-type and mutant groups had a dem-
onstrated increase in PFS from the addition of everolimus. By 
mutation site, the benefit was evident for the D538G subgroup. 
The study lacked sufficient numbers of patients with Y537S 
to draw conclusions on everolimus benefit for this subgroup. 
An interaction between specific alleles and mTOR activity has 
not been biologically identified. Therefore, this particular data 
are hypothesis generating and further biological and clinical 
investigation into potential ESR1 mutant allele-specific effects 
should be encouraged.
CDK4/6 inhibitors
The addition of CDK4/6 inhibitors to ET is one of the major break-
throughs in breast oncology over the last few years. Palbociclib 
is currently used in routine clinical practice in the USA both in 
first- and second-line setting following its approval by the Food 
and Drug Administration based on three randomized clinical 
trials (PALOMA 1, 2, and 3) (40, 41, 45) that demonstrated a 
significant benefit in terms of PFS and clinical benefit rate with 
its addition to endocrine agents.
The PALOMA3 trial evaluated the combination of palbociclib 
with fulvestrant in AI-resistant patients (41). The ESR1 mutation 
status was analyzed in 69% of all patients, with ESR1 mutations 
detected in 25.3% of cases (23). There was a predominance of 
mutations in D538G, Y537N, Y537S, and E380Q. Mutations were 
polyclonal in 28.6% of cases. Characteristics associated with ESR1 
mutation were sensitivity to prior ET, bone metastases, and prior 
lines of therapy for metastatic disease. The benefit from palboci-
clib was seen irrespective of ESR1 mutation status.
Many patients with metastatic ER-positive HER2-negative 
breast cancer now receive letrozole and palbociclib as first-line 
ET (46). Although Fribbens et  al. (23) showed encouraging 
activity of both fulvestrant and palbociclib against ESR1-mutant 
cancers, it is not known how palbociclib will affect the emergence 
of ESR1 mutations or whether fulvestrant plus palbociclib will 
have the same benefit in patients with prior palbociclib exposure 
(47). A recent report suggests that treatment with palbociclib and 
letrozol does not prevent selection of ESR1 mutations (23).
Data from clinical trials demonstrating clinical benefits have 
been reported for two other inhibitors of CDK4 and CDK6 
(namely, ribociclib and abemaciclib) (42, 48). At the present time, 
no data on the potential interaction of ESR1 mutations with these 
targeted agents have been reported.
eSR1 MUTATiON AS A THeRAPeUTiC 
TARGeT
Targeted therapy directed to ESR1-mutated clones is an appealing 
concept, and preclinical and clinical development of rationale-
based novel therapeutic strategies that inhibit these ER mutants 
has the potential to substantially improve treatment outcomes. 
New-generation SERMs and SERDs, such as bazedoxifene (49) 
and ARN 810 (50), are being studied in initial phase I/II clini-
cal trials after preclinical evidence of efficacy in the inhibition 
of ER-LBD mutants (2, 51). AZD9496, a non-steroidal small 
molecule, which is a potent and selective antagonist and down-
regulator of ERα can potently bind and downregulate D538G and 
Y537C/N/S ERα proteins in vitro (52).
The activity of mutated ER remains highly dependent on the 
recruitment of coactivators; therefore, new agents targeting ER 
coactivators, such as small-molecule SRC-3 inhibitors, might 
offer another approach to target the ER mutants and should be 
tested alone and in combination with ER antagonists (53).
The presence of ESR1 mutations is associated with other 
genetic and epigenetic alterations; therefore, testing of novel ther-
apeutic agents and their combinations in preclinical models that 
include different genetic backgrounds is crucial and highlights 
the potential of patient-derived xenografts and ex vivo cultures 
of circulating tumor cells (CTCs) from patients with metastatic 
ER+ breast cancer.
Indeed, a recent report successfully used ex vivo cultures of 
CTCs harboring ER mutants to tailor different therapeutic com-
binations. Yu et  al. (54) tested inhibitors of multiple pathways, 
alone or in combination with ER inhibitors. The results were 
highly complex and varied between the two available models, 
but the study identified the efficacy of mTOR, PI3K, and heat 
shock protein 90 (HSP90) inhibitors in this setting, especially 
in combination with fulvestrant. Targeting HSP 90, which is the 
chaperone protein of ER, may be useful to treat Y537S ESR1-
mutated tumors. The authors showed that mutant ESR1 tumors 
are highly dependent on HSP90 and preclinical studies with the 
HSP90 inhibitor STA9090 demonstrated cytotoxicity alone and 
in combination with raloxifene and fulvestrant to ex vivo cul-
tured circulating breast tumor cells (54). Interestingly, they also 
described that the allele frequency of ESR1 mutation correlated 
with the sensitivity to HSP90 inhibition.
On the basis of the available studies, new therapeutic strate-
gies should first be studied in preclinical models that accurately 
demonstrate the genomic complexity of individual tumors. If 
successfully translated to the clinical setting, our abilities to bet-
ter detect the mutations, predict resistance, and effectively treat 
tumor harboring these mechanisms of resistance will have an 
important impact on patient outcomes.
FUTURe PeRSPeCTiveS
A strategy for individualized, biomarker-driven selection of tar-
geted agents and an integrated method for detecting reproducible 
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key molecular alterations, which cause resistance to ET, are man-
datory for future precision medicine in this subset of breast 
cancer (55).
Alternative approaches enabling the detection of the mutation 
in liquid biopsies, including the analysis of cfDNA from blood 
samples, along with additional ultrasensitive methods are in 
development. Methodological assays to detect and quantify ESR1 
mutations in blood and tissue must now be standardized before 
potential clinical use. It should be noted that there may be other 
mutations or aberrations in ESR1, such as amplification or trans-
locations, which could also contribute to AI resistance (1). ESR1 
mutations are generally clustered between amino acids 534–538, 
though mutations at other positions, including S463 and E380, 
have also been described (1, 2, 25). Four hot spot mutations 
(D538G, Y537S/N/C) contribute to approximately three-quarters 
of all ESR1 acquired mutations. The question of whether there 
are differences between specific mutations is still unanswered. 
Interestingly, retrospective analysis from the BOLERO-2 trial 
suggest that the benefit of mTOR targeted therapy was seen in 
patients with wild-type ESR1 and ESR1 mutations on codon 538, 
whereas preliminary data showed a potential lack of benefit with 
everolimus in patients with codon 573 mutations (21). These 
associations should be evaluated in further studies.
Although the technical sensitivity of the various approaches 
for mutation detection is known, the level of ctDNA in early-stage 
patients, among different tumor types, or in various clinical sce-
narios has not been characterized. Recent data will now support 
studies on earlier stages of disease. For example, will detection of 
ESR1 mutations during adjuvant AI therapy affect decisions regard-
ing therapy duration and/or a switch to an alternative therapy?
Neoadjuvant ET (NET) is being increasingly studied both 
as a clinical and as a scientific tool (56, 57). The evaluation of 
treatment response in vivo is of the highest importance, especially 
when the disease is still within a “window of curability” (1). Miller 
et al. (58) recently demonstrated that many mutations are newly 
detected or enriched post-NET, including two LBD mutation in 
ESR1 in patients treated with neoadjuvant AI, suggesting that 
ESR1 mutations may be potential mechanisms of resistance to 
ET used in early-stage disease and confirming the notion that 
precision medicine approaches based on genomic analysis of 
a single specimen are likely insufficient to capture all clinically 
significant information.
Future research will address whether analyses based on liq-
uid biopsies can be used as a surrogate for treatment response 
and to monitor disease evolution (59). Another potential use is 
disease monitoring in metastatic patients and early detection of 
progression. As mentioned, mutations were detectable in 75% of 
all cases at least 3 months before progression on AI therapy (22). 
Future clinical trials in advanced breast cancer might consider 
using plasma DNA analysis to optimize ET choice according to 
ESR1 mutation status. An additional open question is whether 
and how more effective endocrine therapies or longer durations 
of adjuvant treatment, by increasing the selection pressure and 
its time-span, will affect the time of emergence and frequency of 
ESR1 mutations.
Translational research strategies such as PDXs and ex vivo 
cultures of CTCs can be used to facilitate the development of 
ESR1-mutant targeted therapies. New therapeutic strategies 
should initially be studied in preclinical models that accurately 
recapitulate the genomic complexity of breast cancer. If success-
fully translated to the clinical setting, our abilities to better detect 
the molecular alterations, predict resistance, and effectively treat 
tumors harboring these mutations will have a substantial impact 
on patient outcome.
Take home messages
– Recurrent activating mutations within the ER LBD have been detected 
in 20–30% of patients with metastatic ER-positive endocrine-resistant 
advanced breast cancer
– ESR1 mutations (ESR1m) confer constitutive ligand-independent activity
– Mechanism of secondary (acquired) resistance to AIs
– Negative prognostic biomarker (inferior survival outcomes)
– May be amendable for monitoring tumor relapse (and earlier treatment 
change?)
– Potential use as predictive biomarker (resistance to further AI monotherapy, 
similar/benefit with fulvestrant HD and combination with CDK4/6 and 
mTOR inhibitors)
– Potential use as therapeutic target (new generations SERMs and SERDs, 
ER coactivator inhibitors)
CONCLUSiON
Hormone receptor-positive advanced breast cancer represents 
a significant clinical problem that is responsible for most breast 
cancer deaths. Historically, ET has been an effective therapeutic 
approach associated with both efficacy and limited toxicity. 
However, our clinical approach to these patients has significant 
limitations. We tend to treat HR+ patients as having the same 
endocrine sensitivity, not considering tumor heterogeneity or 
changes associated with disease progression.
There is an unmet need to generate predictive biomarkers to 
guide more personalized care for these patients. The discovery 
of recurrent ESR1 mutations within the region of the gene that 
encodes the ER-LBD in endocrine-resistant ER+ advanced breast 
cancer introduced new clinical challenges and opportunities for 
the understanding of the mechanisms of endocrine resistance. 
What is clear is that AI-treated tumor cells are adapting to the 
lack of ligand, and a key aspect to understanding AI resistance 
is to sample recurrent tumor cells and monitor the signaling 
pathways that have become active rather than relying purely on 
the prognostic information available from the treatment-naïve 
primary tumor.
At the present time, ESR1 mutation status can be considered 
a negative prognostic biomarker associated with worsened PFS 
and OS. The potential use of ESR1 mutation status as a predic-
tive biomarker to guide the choice of the optimal therapeutic 
strategy is being developed rapidly. Based on current data, ESR1 
mutations are associated with inferior outcomes with further 
AI treatment. Benefits with high-dose fulvestrant and combi-
nations of endocrine agents with targeted therapies (CDK4/6 
inhibitors and mTOR inhibitors) were seen irrespective of 
ESR1 mutation status. Targeting ESR1-mutated clones is an 
appealing concept, and preclinical and clinical development of 
new-generation SERDS and SERMS as well as ER coactivator 
inhibitors is ongoing.
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Integrative approaches using multiple types of data, such as 
more comprehensive analysis of the transcriptome, epigenetic 
regulators of the genome and modern quantitative proteomics 
methods, coupled with a conceptual bioinformatics and sta-
tistical methods that incorporate the intra-tumor genetic and 
phenotypic heterogeneity found in cancers, may result in fun-
damental developments that could potentially be translated into 
clinical benefit for cancer patients (60). Future research efforts 
should allow ESR1 mutational status to be used as an integral 
biomarker in trials on ER-positive breast cancer and to be tested 
prospectively as a stratification factor, as an enrichment strategy 
and as a therapeutic target in the development of new strategies 
to overcome endocrine resistance in breast cancer.
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